Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Russell who wrote (5483)	2/17/1998 9:00:00 AM
From: Tunica Albuginea	Respond to of 23519

Richard, I haven't personally ( yet, G ).My experience reflects the published data.Only difference the success rate is a little lower, about 40%, rather than the published 60%.This may have to do with the population in this aerea, somewhat older with more vascular arteriosclerosis. However with Actis it is now back to approaching the 60% and maybe 65%. For people with psychogenic ED the success is higher but not enough cases to base statistics on. Also in the borderline cases were it takes much longer to achieve erection it works well. It is very important to follow instructions. As Misslil said earlier, it is possible that an " angiogenesis " effect may be taking place were the continued use of Alprostadil may stimulate new vessel formation over the long haul. TA